Laurel VC Acquires Asthma/COPD Technology; Will Form China Biopharma

Laurel Venture Capital, a Hangzhou life science VC, acquired global rights to novel asthma/COPD drug technology from Alpine Immune Sciences of Seattle. Laurel intends to form a China company to develop the technology. The agreement includes global rights to cavosonstat, Alpine's lead drug that is currently in a US Phase II trial. Laurel plans to expand the trial into a global test. Laurel will make an upfront payment and pay future milestones and royalties, though details were not disclosed. More details....

Share this with colleagues:

Original Article: Laurel VC Acquires Asthma/COPD Technology; Will Form China Biopharma

More From BioPortfolio on "Laurel VC Acquires Asthma/COPD Technology; Will Form China Biopharma"